Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. reports developments tied to its clinical-stage targeted protein degradation business, including oncology programs designed with its TORPEDO® platform. Recurring company updates cover cemsidomide, an oral IKZF1/3 degrader being studied in relapsed/refractory multiple myeloma, as well as broader degrader-medicine research intended to address disease-causing proteins.
Company news also includes collaboration activity, such as its Roche agreement for degrader-antibody conjugates, along with clinical disclosures, operating and financial results, conference participation, equity inducement grants, and other governance matters under Nasdaq rules.
C4 Therapeutics, a biopharmaceutical company, announced its participation in the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 2:50 p.m. ET. This event will showcase C4T's pioneering approach to developing small-molecule medicines that target and degrade disease-causing proteins. A live webcast of the presentation will be available in the Investors section of their website, with a replay accessible for two weeks post-event. C4T focuses on cancer and neurodegenerative disease treatments, emphasizing advantages like higher potency and reduced side effects.
C4 Therapeutics (Nasdaq: CCCC) has submitted an Investigational New Drug (IND) application for its lead candidate CFT7455, aimed at treating hematologic malignancies, with FDA review underway. A Phase 1/2 trial is anticipated to begin in the first half of 2021. Additionally, C4T plans to submit an IND for CFT8634 in the second half of 2021 and advance BRAF and RET programs into IND-enabling studies later this year. The company expects its current cash reserves of approximately $370 million to support operations through the end of 2023.
C4 Therapeutics, Inc. (Nasdaq: CCCC) has been added to the Russell 2000® and Russell 3000® Indexes, effective December 21, 2020. This inclusion follows their IPO just two months earlier and aims to enhance the company's visibility to investors. The Russell 2000® Index tracks small-cap stocks and serves as a benchmark for investment strategies, with around $9 trillion in assets connected to it. C4 Therapeutics focuses on developing small-molecule drugs to degrade disease-causing proteins, targeting cancer and neurodegenerative diseases.
C4 Therapeutics (Nasdaq: CCCC), a biopharmaceutical pioneer in targeted protein degradation, will present at the Evercore ISI 3rd Annual HealthCONx on December 3, 2020, at 8:25 a.m. ET.
Investors can access a live webcast of the presentation on the company’s website, with a replay available for two weeks post-event. C4T focuses on therapeutics that selectively destroy disease-causing proteins, offering potential advantages over traditional treatments, particularly in cancer and neurodegenerative diseases.
C4 Therapeutics (Nasdaq: CCCC), a biopharmaceutical innovator, will present at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 8:30 a.m. ET. C4T specializes in a unique class of small-molecule drugs aimed at selectively degrading disease-causing proteins, targeting conditions like cancer and neurodegenerative diseases. A live webcast of the presentation will be available on their website, with a replay archived for two weeks. This targeted protein degradation approach offers potential advantages over traditional therapies, including reduced drug resistance and fewer side effects.
C4 Therapeutics, Inc. (Nasdaq: CCCC) has reinforced its leadership team with key appointments, including Andrew Hirsch as CEO. The company successfully completed an upsized IPO in October 2020, raising $209.8 million, extending its cash runway into the second half of 2023. For Q3 2020, C4T reported revenues of $8.4 million, up from $5.4 million in Q3 2019, driven by collaboration agreements. However, R&D expenses surged to $23.9 million, resulting in a net loss of $21.8 million. The company anticipates an IND submission for its lead candidate, CFT7455, by the end of 2020.
On October 14-15, 2020, C4 Therapeutics (Nasdaq: CCCC) will present at the 3rd Annual Targeted Protein Degradation Summit. Dr. Rhamy Zeid will discuss the use of C4T’s TORPEDO™ platform for developing selective protein degraders, focusing on CFT8634 for synovial sarcoma. Dr. Stewart Fisher will lead a roundtable on the challenges and opportunities in drug discovery. The company aims to optimize protein degradation to provide new treatments for cancer and neurodegenerative diseases, showcasing its innovative approach in the biopharmaceutical industry.
C4 Therapeutics, a biopharmaceutical company focused on developing small-molecule drugs to degrade disease-causing proteins, announced the successful closing of its initial public offering (IPO) on October 6, 2020. The company sold 11.04 million shares, including 1.44 million additional shares purchased through underwriters' options, priced at $19.00 each. This resulted in gross proceeds of approximately $209.76 million, before expenses. The IPO is managed by Jefferies, Evercore ISI, BMO Capital Markets, and UBS Investment Bank.
C4 Therapeutics (Nasdaq: CCCC) has priced its upsized initial public offering at $19 per share, offering 9.6 million shares for gross proceeds of approximately $182.4 million. The offering is scheduled to begin trading on the Nasdaq Global Market on October 2, 2020, and is expected to close on October 6, 2020, pending customary closing conditions. The company has also granted underwriters a 30-day option to purchase an additional 1.44 million shares. C4T focuses on developing small-molecule drugs to selectively degrade disease-causing proteins for cancer and neurodegenerative conditions.